EE199 Cost-Effectiveness of Pembrolizumab for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Colombia

Abstract

Phase III KEYNOTE-048 trial showed that programmed death receptor 1 (PD-1) inhibitor pembrolizumab, in the combined positive score (CPS) ≥1 population and combined with platinum + 5-fluorouracil (5-FU) in the total population, improves overall survival (OS) over cetuximab + platinum + 5-fluorouracil in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This study evaluated the cost-effectiveness of pembrolizumab as combination therapy with platinum-based therapies (cisplatin or carboplatin) plus 5-FU in the CPS≥1 population versus cetuximab + platinum + 5-FU from a third payer perspective in Colombia.